MedTrace Logo

FDG PET Imaging in Diagnosing Patients With Glioblastoma

NCT02885272 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-07-21

No results posted yet for this study

Summary

This early phase I trial studies the how well fluorodeoxyglucose F-18 (FDG) positron emission tomography (PET) imaging works in diagnosing patients with confirmed or suspected glioblastoma. Diagnostic procedures, such as FDG PET, may help find and diagnose glioblastoma.

Conditions

  • Brain Glioblastoma

Interventions

PROCEDURE

Computed Tomography

Undergo PET/CT scans

RADIATION

Fludeoxyglucose F-18

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo standard of care MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/CT scans

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Jason M Johnson · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-28
Primary Completion
2022-07-12
Completion
2022-07-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02885272 on ClinicalTrials.gov